Sort By:
Date
Title
Category:

Claes Buxfeldt joins NDA Group as new HTA Director

Claes brings with him a wealth of knowledge and experience from his time in industry. For clients leading drug development consultancy this means faster provision of market access enabling advice and support.

| Community News, Library News, Services News, Social News

NDA Group celebrates 20 years of championing treatments for rare diseases

Over the years NDA has been involved in the development of more than 50 products for individuals with rare diseases.

| Community News, Library News, Services News, Social News

Senior Consultant, US West Coast

Are you an experienced specialist in regulatory affairs within drug development? Become a part of NDA’s growing, highly qualified team!

| Community News, Library News, Services News, Social News

NDA Group welcomes proposal for new HTA regulation in Europe

The particular focus on Relative Effectiveness Assessment, the establishment of a new Coordination Group of clinical experts from the Member States and the continuation of the practices established by the voluntary European HTA network were all cited as reasons for a promising future for the regulation.

| Community News, Health Technology Assessment, Library News, Services News

Andrew Monaghan joins NDA Group as UK General Manager

Andrew brings over 35 years’ of experience in the drug development industry to the well-established UK team of close to 50 consultants and support staff.

| Community News, Library News, Services News

Common failures in drug development

Dr. Lönngren will present and discuss the common failures in drug development from a regulatory and market access perspective and how to avoid these failures.

| Community News, Health Technology Assessment, Library News, Presentations and Infographics, Services News

Dr. Lönngren presents on hot topics at ARCS Executive Round Table

Dr. Lönngren will address hot topics such as Brexit, expedited pathways, use of RWE in decision making, cost effectiveness and affordability.

| Community News, Presentations and Infographics, Services News

Meet us at the Phacilitate Cell & Gene Therapy World 2018

NDAs Dr Paula Salmikangas will be moderating a 1-hour ‘Working Lunch’ Panel Discussion on “Safety aspects of genetically modified cells”.

| Community News, Library News, Presentations and Infographics, Services News

Free Webinar - Development of Cell based Cancer Immunotherapy products

Join us on 8th February to learn how to maximise safety and efficacy of novel cell-based cancer treatments.

| Community News, Library News, Presentations and Infographics, Services News

NDA Advisory Board expands to improve access to world leading oncology expertise

We are expanding our unique NDA Advisory Board with the appointment of Dr. Susan Jerian a NCI trained oncologist with over two decades of leadership and experience in the Industry and the FDA.

| Community News, Library News, Oncology, Services News, Social News

Meet us around JP Morgan

NDA is on site in San Francisco around JP Morgan 6-10th of January. Meet us there!

|

2018 – The future of biotech

What will 2018 look like for biotech? NDA's CEO, Johan Strömquist, examines some key trends.

|

Happy Holidays & Happy New Year

We are pleased to make a contribution to Médecins Sans Frontières to support their work instead of sending a seasonal card this year.

| Community News, Library News, Social News

Assessing the consequences of the EMA's relocation

The EMA is relocating to Amsterdam – but what are the consequences to the Agency’s priorities and to the industry?

| Articles, Community News, Library News, Services News

Strategic alliance to support efficient, ethical practices in biopharma industry

New Collaboration offers broad range of Compliance-and Risk Management Strategies in Europe and US to Life Science Industry.

| Community News, Library News, Pharmacovigilance, Services News, Social News